Conference item icon

Conference item

Safety of hydrofluoroalkane-134a beclomethasone dipropionate extrafine aerosol.

Abstract:

Herein we assess the safety of an inhaled formulation of beclomethasone dipropionate (BDP) which uses the propellant hydrofluoroalkane-134a (HFA) for the treatment of asthma. Acute local tolerability (as assessed by the incidence of cough and mean forced expiratory volume after 1 s inhalation) was similar for both BDP and placebo formulated in either chlorofluorocarbon (CFC) or HFA propellants. A total of 43 patients were treated with HFA-BDP (0, 200, 400 or 800 micrograms day-1) or CFC-BDP (...

Expand abstract
Publication status:
Published

Actions


Access Document


Authors


Volume:
92 Suppl A
Issue:
SUPPL. A
Pages:
33-39
Host title:
Respiratory medicine
Publication date:
1998-06-01
Event location:
ENGLAND
DOI:
EISSN:
1532-3064
ISSN:
0954-6111
Source identifiers:
138633

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP